CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

被引：1

作者：

Soo, R. A. ^{[1
]}

Cho, B. C. ^{[2
]}

Kim, J-H. ^{[3
]}

Ahn, M-J. ^{[4
]}

Lee, K. H. ^{[5
,12
]}

Zimina, A. ^{[6
]}

Orlov, S. ^{[7
]}

Bondarenko, I. ^{[8
]}

Lee, Y-G. ^{[9
]}

Ni, L. Yueh ^{[10
]}

Lee, S. S. ^{[11
]}

Lee, K. H. ^{[5
,12
]}

Pang, Y. K. ^{[13
]}

Fong, C. H. ^{[14
]}

Kang, J. H. ^{[15
]}

Lim, C. S. ^{[16
]}

Danchaivijitr, P. ^{[17
]}

Lee, H. ^{[18
]}

Park, S. ^{[18
]}

Cicin, I. ^{[19
]}

机构：

[1] Natl Univ Canc Inst Singapore, Haematol Oncol Dept, Singapore, Singapore

[2] Yonsei Univ, Yonsei Canc Ctr, Internal Med, Coll Med, Seoul, South Korea

[3] CHA Bundang Med Ctr, Seongnam, South Korea

[4] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea

[5] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Med, Coll Med, Cheongju, South Korea

[6] State Budgetary Healthcare Inst Omsk Reg, Omsk, Russia

[7] Pavlov State Med Univ, Oncol, St Petersburg, Russia

[8] Dnipropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnipro, Ukraine

[9] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Sch Med, Seoul, South Korea

[10] Hosp Umum Sarawak, Sarawak, Malaysia

[11] Inje Univ, Haeundae Paik Hosp, Coll Med, Busan, South Korea

[12] Yeungnam Univ, Dept Internal Med, Med Ctr, Daegu, South Korea

[13] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia

[14] Hosp Pulau Pinang, Dept Radiotherapy & Oncol, Georgetown, Malaysia

[15] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea

[16] Hosp Sultan Ismail, Oncol Dept, Johor Baharu, Malaysia

[17] Mahidol Univ, Fac Med, Dept Med, Siriraj Hosp, Bangkok, Thailand

[18] Yuhan Corp, Seoul, South Korea

[19] Trakya Univ, Med Oncol Dept, Med Fac, Edirne, Turkiye

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2357

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1324MO

引用

页数：2

共 50 条

[21] Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Passaro, A.
Cho, B. C.
Wang, Y.
Melosky, B.
Califano, R.
Lee, S-H.
Girard, N.
Reckamp, K. L.
Takahashi, T.
Felip, E.
Gentzler, R. D.
Popat, S.
William, W. Nassib, Jr.
Sun, T.
Shah, S.
Diorio, B.
Knoblauch, R. E.
Bauml, J. M.
Garcia-Campelo, M. R.
Wang, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1307 - S1307
[22] Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis
Lu, S.
Cho, B. C.
Lee, J-S.
Lee, S-H.
Danchaivijitr, P.
Liu, B.
Alip, A.
Xiong, H.
How, S. H.
Chang, G-C.
Yang, J. C-H.
Yoshioka, H.
Xia, K.
Martinez, M.
Bauml, J. M.
Sethi, S.
Hayashi, H.
ANNALS OF ONCOLOGY, 2023, 34 : S1661 - S1661
[23] Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2
Cho, Byoung Chul
Wang, Yongsheng
Felip, Enriqueta
Cui, Jiuwei
Spira, Alexander I.
Neal, Joel W.
Baik, Christina
Marmarelis, Melina Elpi
Ichihara, Eiki
Lee, Jong-Seok
Lee, Se-Hoon
Yang, James Chih-Hsin
Michels, Sebastian Yves Friedrich
Anastasiou, Zacharias
Curtin, Joshua C.
Lyu, Xuesong
Leconte, Isabelle
Trani, Leonardo
Baig, Mahadi
Tomasini, Pascale
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.
Chouaid, Christos
Luciani, Laura
Le Lay, Kate
De Pouvourville, Gerard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases
Zheng, X.
An, J.
Hua, Y.
Ding, X.
Sun, S.
Shi, H.
Zhou, L.
Xu, W.
Wei, F.
Wang, K.
Li, X.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S348 - S348
[26] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
Liu, Ao
Wang, Xiaoming
Wang, Lian
Zhuang, Han
Xiong, Liubo
Gan, Xiao
Wang, Qian
Tao, Guanyu
BMC CANCER, 2024, 24 (01)
[27] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
Nguyen, D.
Besse, B.
Cho, B. C.
Lee, S. -H.
Lee, K. H.
Lu, S.
Cheng, Y.
Yao, Y.
Girard, N.
Lin, C. -C.
Felip, E.
Aguilar, A.
Charoentum, C.
Cruz, F. J. S. M.
Majem, M.
Lim, C. S.
Akamatsu, H.
Hayashi, H.
Yang, J. C. -H.
Kowalyszyn, R.
Tiscoski, K.
Franke, F.
Ponomarenko, D.
Arslan, C.
Forster, M.
Urban, D.
Misch, D.
Delmonte, A.
Montes, L. V. G.
Gadgeel, S. M.
Cruz-Correa, M.
Peguero, J.
Rousey, S.
Gaffar, Y.
Owen, S.
Schuchard, J.
Diels, J.
Sermon, J.
Sun, T.
Ennis, M.
Fennema, E.
Daksh, M.
Sethi, S.
Bauml, J. M.
Garcia Campelo, M. R.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
[28] Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data
Moulson, Ruth
Law, Jennifer
Sacher, Adrian
Liu, Geoffrey
Shepherd, Frances
Bradburyb, Penelope
Eng, Lawson
Iczkovitz, Sandra
Abbie, Erica
Elia-Pacitti, Julia
Ewara, Emmanuel M.
Mokriak, Viktoriia
Weiss, Jessica
Pettengell, Christopher
Leighl, Natasha
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E12 - E13
[29] PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
Prabhash, K.
Noronha, V.
Patil, V.
Joshi, A.
Chougule, A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S395 - S395
[30] High-dose almonertinib in treatment-naive EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.
Fan, Yun
Li, Hui
Xu, Yanjun
Huang, Zhiyu
Qin, Jing
Zhou, Rongrong
He, Jing-Dong
Zhu, Junfei
Yu, Sz
Chen, Kaiyan
Han, Guang
Chen, Jun
Tan, Wei
Gong, Lei
Lou, Guangyuan
Ren, Biyong
Chen, Xiangqi
Zhang, Dianbao
Lu, Hongyang
Hong, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →